Switzerland
Novocure is a global oncology company with the mission of extending survival in aggressive forms of cancer. The company's innovative therapy, Tumor Treating Fields, is aimed at making a difference in cancer treatment. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. The company also has ongoing or completed clinical trials in various other cancer types such as brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and gastric cancer.
Founded in 2000, Novocure is headquartered in Switzerland with operations in the U.S. and offices in Canada, Germany, Jersey, Japan, and Israel. The company recently received a $100.00M Post-IPO Debt investment on May 2, 2024 from Pharmakon Advisors.
Novocure's dedication to pushing the boundaries of cancer treatment, along with its global presence and recent investment, demonstrates its potential for impacting the biotechnology and healthcare industries.
